REFERENCES
1. Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027-50.
3. Powell-Wiley TM, Poirier P, Burke LE, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984-1010.
4. Szabo L, McCracken C, Cooper J, et al. The role of obesity-related cardiovascular remodelling in mediating incident cardiovascular outcomes: a population-based observational study. Eur Heart J Cardiovasc Imaging. 2023;24:921-9.
5. Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta. 2016;1861:1555-68.
6. Mohammed AS, Ahmed H, Singh S, et al. Impact of metabolically healthy obesity on cardiovascular outcomes in older adults with HFpEF: insights from a nationwide sample. J Clin Med. 2025;14:5495.
7. Su Y, Li Y, Ding R, et al. Association between metabolically healthy obesity and risk of dementia: a systematic review and meta‐analysis. Med Adv. 2024;2:176-85.
8. Aggarwal R, Harling L, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. The effects of bariatric surgery on cardiac structure and function: a systematic review of cardiac imaging outcomes. Obes Surg. 2016;26:1030-40.
9. Huang J, Liu M, Su E, et al. Elevated circulating high-sensitivity cardiac troponin t and cardiac remodeling in obesity. BMC Cardiovasc Disord. 2021;21:620.
10. Pontone G, Guaricci AI, Andreini D, et al. Prognostic benefit of cardiac magnetic resonance over transthoracic echocardiography for the assessment of ischemic and nonischemic dilated cardiomyopathy patients referred for the evaluation of primary prevention implantable cardioverter-defibrillator therapy. Circ Cardiovasc Imaging. 2016;9:e004956.
11. Abid MA, Asad MB, Razzak MJ. Natural peptides versus semaglutide: a safer approach to obesity management. Med Adv. 2025;3:202-4.
12. Holloway CJ, Cochlin LE, Emmanuel Y, et al. A high-fat diet impairs cardiac high-energy phosphate metabolism and cognitive function in healthy human subjects. Am J Clin Nutr. 2011;93:748-55.
13. Larios G, Uribe S, Trincado C, et al. Myocardial function, mechanics and work by echocardiography in adolescents with severe obesity. Cardiovasc Endocrinol Metab. 2024;13:e0301.
14. Bakhtiyari M, Kazemian E, Kabir K, et al. Contribution of obesity and cardiometabolic risk factors in developing cardiovascular disease: a population-based cohort study. Sci Rep. 2022;12:1544.
15. Liu J, Li J, Yu J, et al. Regional fat distributions are associated with subclinical right ventricular dysfunction in adults with uncomplicated obesity. Front Cardiovasc Med. 2022;9:814505.
16. De Luca M, Shikora S, Eisenberg D, et al. Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO/ASMBS). Obes Surg. 2024;34:3963-4096.
17. Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1-203.
18. Ponikowski ADGDTP, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol. 2016;69:1167.e1-85.
19. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
21. Sha R, Baines O, Hayes A, et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options. J Am Heart Assoc. 2024;13:e032277.
22. Tian Y, Yang J, Lan M, Zou T. Construction and analysis of a joint diagnosis model of random forest and artificial neural network for heart failure. Aging. 2020;12:26221-35.
23. Pinheiro LCHT, Rossi M, Dos Santos CAF, et al. Prevalence of associations among sarcopenia, obesity, and metabolic syndrome in Brazilian older adults. Front Med. 2023;10:1206545.
24. Lieb W, Gona P, Larson MG, et al. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014;7:870-8.
25. Gao Y, Ren Y, Guo YK, et al. Metabolic syndrome and myocardium steatosis in subclinical type 2 diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Cardiovasc Diabetol. 2020;19:70.
26. Levelt E, Mahmod M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016;65:44-52.
27. Hirose K, Nakanishi K, Daimon M, et al. Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese japanese subjects in a general community. Cardiovasc Diabetol. 2021;20:22.
28. Deng J. Research progress on the molecular mechanism of coronary microvascular endothelial cell dysfunction. Int J Cardiol Heart Vasc. 2021;34:100777.
29. Bugger H, Byrne NJ, Abel ED. Animal models of dysregulated cardiac metabolism. Circ Res. 2022;130:1965-93.
30. Cao Y, Wang Y, Zhou Z, et al. Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure. Science. 2022;377:1399-406.
31. Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17:773-91.
32. Cheng PN, Chen WJ, Hou CJ, et al. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases. Clin Mol Hepatol. 2024;30:16-36.
33. Zhou XD, Cai J, Targher G, et al; CHESS-MAFLD consortium. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21:270.
34. Yang K, Song M. New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut-liver-heart crosstalk. Nutrients. 2023;15:3970.
35. Sonaglioni A, Cerini F, Fagiani V, et al. Effect of metabolic dysfunction-associated steatotic liver disease (MASLD) on left ventricular mechanics in patients without overt cardiac disease: a systematic review and meta-analysis. J Clin Med. 2025;14:2690.
36. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346.
37. Chen Y, Cheng X, Li S, Yin Y, Xing S, Guo Y. Insulin-like growth factor-1 levels are associated with interventricular septal thickening. Front Endocrinol. 2022;13:997023.
38. Zhao Z, Gao Y, Lin J, et al. Association of depression with long-term cardiovascular risks in older patients with obstructive sleep apnea. Nat Sci Sleep. 2023;15:1033-43.
39. Li Y, He Q, Chen S, et al. BI-7273, a BRD9 inhibitor, reduces lipid accumulation by downregulating the AKT/mTOR/SREBP1 signaling pathway. Biochem Pharmacol. 2024;226:116412.
40. Cui X, Wang J, Zhang Y, Wei J, Wang Y. Plin5, a new target in diabetic cardiomyopathy. Oxid Med Cell Longev. 2022;2022:2122856.
41. Kianu Phanzu B, Nkodila Natuhoyila A, Kintoki Vita E, M’Buyamba Kabangu JR, Longo-Mbenza B. Association between insulin resistance and left ventricular hypertrophy in asymptomatic, black, sub-Saharan African, hypertensive patients: a case-control study. BMC Cardiovasc Disord. 2021;21:1.
42. Catena C, Brosolo G, Da Porto A, et al. Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension. Front Cardiovasc Med. 2022;9:1030968.
43. Kay FU, Abbara S, Joshi PH, Garg S, Khera A, Peshock RM. Identification of high-risk left ventricular hypertrophy on calcium scoring cardiac computed tomography scans: validation in the DHS. Circ Cardiovasc Imaging. 2020;13:e009678.
44. Sparapani R, Dabbouseh NM, Gutterman D, et al. Detection of left ventricular hypertrophy using Bayesian additive regression trees: the MESA. J Am Heart Assoc. 2019;8:e009959.
45. Liu CM, Hsieh ME, Hu YF, et al. Artificial intelligence-enabled model for early detection of left ventricular hypertrophy and mortality prediction in young to middle-aged adults. Circ Cardiovasc Qual Outcomes. 2022;15:e008360.
46. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29:2909-18.
47. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16.
